Biosimilars unlikely to be commercialized within 2 or 3 years

The government will need to proceed with biosimilar projects with more caution as the availability of second generation biologic products that offer superior dosing and/or therapeutic efficacy to the original reference brand is something of a double-edged sword for first generation biosimilars, according to a lawmaker.

The Ministry of Knowledge Economy announced in July that said it would in...